Olema Pharmaceuticals (OLMA) Non-Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Non-Current Assets data on file, last reported at $17.4 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 34.22% year-over-year to $17.4 million in Q1 2026; TTM through Mar 2026 was $67.8 million, a 35.51% increase from a year earlier, with the FY2025 full-year figure at $18.0 million, up 43.75% from the prior year.
• Non-Current Assets for Q1 2026 stood at $17.4 million, down from $18.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for OLMA reached as high as $18.1 million in Q3 2025 and fell as low as $6.1 million in Q2 2023.
• Historically, Non-Current Assets has averaged $11.3 million across 5 years, with a median of $11.6 million in 2024.
• Across the five-year window, Non-Current Assets jumped 595.37% in 2022 and decreased 19.26% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $6.7 million in 2022, then soared by 54.64% to $10.4 million in 2023, then climbed by 19.88% to $12.5 million in 2024, then surged by 43.75% to $18.0 million in 2025, then dropped by 3.13% to $17.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $17.4 million in Q1 2026, $18.0 million in Q4 2025, and $18.1 million in Q3 2025.